Polyphenol Metabotypes in People with Diabetes Type 2
Launched by UNIVERSITY HOSPITAL, GHENT · Jan 31, 2025
Trial Information
Current as of November 10, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain compounds called polyphenols, which are found in foods like fruits and vegetables, are processed in people with Type 2 Diabetes (T2DM) compared to those without diabetes. The researchers want to learn more about how factors like how quickly food moves through the digestive system and the health of gut bacteria can affect this process. By understanding these differences, they hope to find better ways to support people with diabetes.
To be part of the study, participants need to be between 40 and 85 years old and either have Type 2 Diabetes diagnosed for at least two years or be healthy individuals without diabetes. They should also have a body mass index (BMI) between 18.5 and 30 and no other major health issues. During the trial, participants will provide information about their health and may undergo tests related to their diet and health. It’s important to know that this study is not yet recruiting participants, so you can keep an eye out for updates if you or someone you know is interested in being involved.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all participants
- • between 40-85 years
- • age-matched individuals without diabetes
- • BMI between 18.5-30
- • no metabolic syndrome
- • persons with T2DM
- • at leats 2 years of clinical diagnoses of T2DM
- • stable medication use for at least 1 month
- Exclusion Criteria:
- • pregnancy of breastfeeding
- • in last month
- • acute use of anti/pre/probiotics
- • start of new drug or dietary supplements
- • major changes in diet
- • major lifestyle changes
- • diseases
- • Gastrointestinal diseases (inflammatory bowel disease)
- • Bariatric surgery
- • Other forms of diabetes (cystic fibrosis/MODY/T1DM)
- • Heart problems (NYHA 3/4) or previous cardiovascular events
- • Liver problems: non-alcohol steatohepatitis (NASH) and cirrhosis
- • Lung problems (COPD - GOLD 3/4), cystic fibrosis
- • Uncontrolled thyroid function disruption in the past 6 months
- • Intake of coumarin derivatives and direct oral anticoagulant medication
- • Anti-cancer treatment: chemo-/immunotherapy
- • Immonosuppressants (transplant)
- • Antiepileptic drugs
About University Hospital, Ghent
University Hospital Ghent is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. Located in Ghent, Belgium, the hospital is affiliated with Ghent University, fostering a collaborative environment that integrates cutting-edge medical research with high-quality patient care. With a diverse range of specialized departments and a dedicated team of researchers and clinicians, University Hospital Ghent is at the forefront of developing new therapies and improving treatment protocols, aiming to enhance patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ghent, East Flanders, Belgium
Patients applied
Trial Officials
Bruno Lapauw, Professor
Principal Investigator
University Hospital, Ghent
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported